Next Article in Journal
Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy
Next Article in Special Issue
Recent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma
Previous Article in Journal
Bacteriophage Mediates Efficient Gene Transfer in Combination with Conventional Transfection Reagents
Previous Article in Special Issue
From Immunodeficiency to Humanization: The Contribution of Mouse Models to Explore HTLV-1 Leukemogenesis
Article Menu

Export Article

Open AccessReview
Viruses 2015, 7(12), 6490-6505; doi:10.3390/v7122952

Roles of HTLV-1 basic Zip Factor (HBZ) in Viral Chronicity and Leukemic Transformation. Potential New Therapeutic Approaches to Prevent and Treat HTLV-1-Related Diseases

1
CPBS, CNRS FRE3689, Université Montpellier, 34293 Montpellier, France
2
Département des Sciences Biologiques, and Centre de Recherche BioMed Université du Québec à Montréal, Montréal, QC H2X 3X8, Canada
3
Laboratoire de Virologie-EA4537, Centre Hospitalier et Universitaire de Martinique, Fort de France, Martinique
*
Author to whom correspondence should be addressed.
Academic Editor: Louis M. Mansky
Received: 15 October 2015 / Revised: 24 November 2015 / Accepted: 1 December 2015 / Published: 9 December 2015
(This article belongs to the Special Issue Recent Advances in HTLV Research 2015)
View Full-Text   |   Download PDF [560 KB, uploaded 9 December 2015]   |  

Abstract

More than thirty years have passed since human T-cell leukemia virus type 1 (HTLV-1) was described as the first retrovirus to be the causative agent of a human cancer, adult T-cell leukemia (ATL), but the precise mechanism behind HTLV-1 pathogenesis still remains elusive. For more than two decades, the transforming ability of HTLV-1 has been exclusively associated to the viral transactivator Tax. Thirteen year ago, we first reported that the minus strand of HTLV-1 encoded for a basic Zip factor factor (HBZ), and since then several teams have underscored the importance of this antisense viral protein for the maintenance of a chronic infection and the proliferation of infected cells. More recently, we as well as others have demonstrated that HBZ has the potential to transform cells both in vitro and in vivo. In this review, we focus on the latest progress in our understanding of HBZ functions in chronicity and cellular transformation. We will discuss the involvement of this paradigm shift of HTLV-1 research on new therapeutic approaches to treat HTLV-1-related human diseases. View Full-Text
Keywords: human T-cell leukemia virus type 1; adult T-cell leukemia; HTLV-1 bZip Factor; Valproate human T-cell leukemia virus type 1; adult T-cell leukemia; HTLV-1 bZip Factor; Valproate
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Mesnard, J.-M.; Barbeau, B.; Césaire, R.; Péloponèse, J.-M. Roles of HTLV-1 basic Zip Factor (HBZ) in Viral Chronicity and Leukemic Transformation. Potential New Therapeutic Approaches to Prevent and Treat HTLV-1-Related Diseases. Viruses 2015, 7, 6490-6505.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top